Literature DB >> 8425699

Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration.

E M Tarazi1, J G Harter, H J Zimmerman, K G Ishak, R A Eaton.   

Abstract

BACKGROUND: Recent emphasis on nonsteroidal anti-inflammatory drug (NSAID)-associated hepatic injury blurs differences between NSAIDs. Accordingly, examination of hepatic injury by individual NSAIDs seemed warranted. Sulindac-associated hepatic injury was selected.
METHODS: From 338 reports submitted to the Food and Drug Administration, 247 were considered inadequate or unconvincing for sulindac toxicity. The remaining 91 cases of reactions to the drug were analyzed. In 15 there was histological material available.
RESULTS: There were four deaths, three attributed to severe hypersensitivity and one to fulminant hepatic failure. Two thirds of the cases had clinical hallmarks of hypersensitivity. The ratio of females to males was 3.5:1; 69% of the patients were over 50 years of age. Jaundice was recorded in 67% of the patients. The pattern was cholestatic in 43%, hepatocellular in 25%, mixed in 12%, and indeterminate in 20% of the patients. Eosinophilia was significantly more frequent in patients with cholestatic injury (40%) than in those with hepatocellular injury (0).
CONCLUSION: Sulindac injury involves females more than males. It can lead to cholestatic or hepatocellular injury, most often because of immunological idiosyncrasy. In some patients, metabolic idiosyncrasy may be the mechanism. This study illustrates the utility of analysis of adverse reaction reports in characterizing drug-induced injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425699     DOI: 10.1016/0016-5085(93)90428-f

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment.

Authors:  Wei Zou; Robert A Roth; Husam S Younis; Lyle D Burgoon; Patricia E Ganey
Journal:  Toxicology       Date:  2010-04-03       Impact factor: 4.221

Review 2.  Drug-induced liver disorders: implications for drug development and regulation.

Authors:  N Kaplowitz
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

Authors:  Jin Kyung Lee; Mary F Paine; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

Review 4.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 5.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

6.  Medical Care of the Patient With Compensated Cirrhosis.

Authors:  Jorge L Herrera; Reynaldo Rodríguez
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

Review 7.  Hepatotoxicity related to antirheumatic drugs.

Authors:  Guruprasad P Aithal
Journal:  Nat Rev Rheumatol       Date:  2011-01-25       Impact factor: 20.543

8.  Drug-induced Liver Injury.

Authors:  Stefan David; James P Hamilton
Journal:  US Gastroenterol Hepatol Rev       Date:  2010-01-01

Review 9.  Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.

Authors:  A V Manoukian; J L Carson
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

10.  Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

Authors:  Wei Zou; Sachin S Devi; Erica Sparkenbaugh; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2008-12-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.